Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN By Ogkologos - January 9, 2026 518 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the GORTEC 2018-01 NIVOPOST-OP study Source RELATED ARTICLESMORE FROM AUTHOR Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... European Parliament Report on Europe’s Beating Cancer Plan Strengthens Commitment to Rare Cancer Care Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence MOST POPULAR DNA from Ancient Viruses Helps Many Cancers Grow September 6, 2024 Jennifer Garner Shared A Video Of Her Mammogram Appointment October 21, 2019 Study Explores Jaw Problem Linked to Zoledronic Acid, Finds Risk Factors January 28, 2021 Feeling the pull: Using magnetic drug targeting to improve chemotherapy in... February 16, 2023 Load more HOT NEWS What Are Clinical Practice Guidelines and How Do They Impact Care... Implementation of Door-to-Door HPV-based Cervix Screening Results in Better Attendance of... FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine... EMA Recommends Extension of Indications for Blinatumomab
